Inhibikase Therapeutics, Inc. (IKT) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-30

Inhibikase Therapeutics, Inc. (IKT) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-30. 3 Form 8-K material event filings were reported by IKT in the last 90 days. InsiderAlpha tracks every IKT SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Inhibikase Therapeutics, Inc. (IKT)

SEC CIK	0001750149

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-30

Recent IKT Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-02-21	Aurentz Vincent	Insider	D — Derivative transaction	255.3K	$0.00	—	SEC
2026-02-21	Cabell Christopher	President & Head of R&D	D — Derivative transaction	338.3K	$0.00	—	SEC
2026-02-21	Munshi Amit	Insider	D — Derivative transaction	19.1K	$0.00	—	SEC
2025-02-21	Munshi Amit	Insider	A — Grant or award	57.3K	$0.00	—	SEC
2024-10-21	Kush Arvind	Insider	P — Open-market purchase	145.0K	$1.37	$199K	SEC
2024-10-21	Munshi Amit	Insider	P — Open-market purchase	365.0K	$1.37	$500K	SEC
2024-10-21	Bellini Roberto	Insider	P — Open-market purchase	1.46M	$1.37	$2.00M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Inhibikase Therapeutics, Inc. (IKT). Updated in real time as new filings are submitted to the SEC.

Most-Active IKT Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
BERMAN DENNIS N	1	—
Munshi Amit	1	—
Aurentz Vincent	1	—
Bellini Roberto	1	—
Kush Arvind	1	—

Recent IKT Form 8-K Material Events

2026-07-14 — Item 8.01, 9.01 [SEC]
2026-06-29 — Item 5.02, 5.03, 5.07, 9.01 [SEC]
2026-05-12 — Item 2.02, 9.01 [SEC]
2026-04-07 — Item 7.01, 9.01 · Clinical · positive [SEC]
Inhibikase Therapeutics announced the enrollment of the first patient in the IMPROVE-PAH Phase 3 study of IKT-001 for pulmonary arterial hypertension treatment. This represents a key milestone in the clinical development program, advancing the company's lead candidate toward pote
2026-03-26 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Inhibikase Therapeutics announced its financial results for the year ended December 31, 2025 and provided corporate updates on March 26, 2026. The filing provides standard annual financial results without explicit beat/miss or guidance language.

Recent Insider Filings

2026-06-30 — BERMAN DENNIS N (Insider)
2026-06-30 — Canner David (Insider)
2026-06-30 — Kush Arvind (Insider)
2026-06-30 — Bellini Roberto (Insider)
2026-06-30 — Aurentz Vincent (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in IKT insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

IKT Insider Trading — FAQ

What is the latest insider trade for IKT?: Inhibikase Therapeutics, Inc. (IKT) had 6 insider filings in the last 90 days, with the most recent on 2026-06-30. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying IKT stock?: 0 insider purchases of IKT were filed in the last 90 days.
How many insiders are selling IKT stock?: 0 insider sales of IKT were filed in the last 90 days.
Where can I see IKT SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every IKT SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live IKT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.